Under the terms of the agreement, which was announced on 29 March 2016, Novartis will continue distributing the brands, indicated for the treatment of medical conditions across a number of therapeutic areas, for a period until all marketing authorizations have been transferred to Sun Pharma’s subsidiary. Marketing and distribution will then be undertaken by a local marketing partner under the Sun Pharma label.

‘This acquisition marks Sun Pharma’s foray into the Japanese prescription market and provides us an opportunity to build a larger product portfolio in the future’ said Dilip Shanghvi, Managing Director of Sun Pharma.

The 14 brands have combined annualized revenues of around US$160 million.

In 2013, Sun Pharma acquired Ranbaxy Laboratories from Japan’s Daiichi Sankyo, elevating the Indian generics manufacturer into the top five drugmakers in the world [1].

Related article
Teva takes over joint venture solidifying its position in Japan

Reference
1. GaBI Online - Generics and Biosimilars Initiative. Sun Pharma to acquire Ranbaxy creating 5th largest generics firm [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2016 Apr 22]. Available from: www.gabionline.net/Pharma-News/Sun-Pharma-to-acquire-Ranbaxy-creating-5th-largest-generics-firm

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2016 Pro PharmaCommunications International. All Rights Reserved.